Biotech · Public company · Norcross, GA, US

Galectin Therapeutics Inc

Ticker GALT · SEC CIK 0001133416

Track this companyFree. Adds Galectin Therapeutics Inc to your Dealase workspace and tells you when its record changes.

Clinical trials60 recruiting or active

Pipeline programs5From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availableNo recent cash burn filed

Pipeline5

Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH CirrhosisPHASE2_PHASE3 · TERMINATED · started Jun 25, 2020ClinicalTrials.gov NCT04365868 · fetched Nov 12, 2026
GT-032 Belapectin Hepatic ImpairmentPHASE1 · COMPLETED · started Jun 16, 2020ClinicalTrials.gov NCT04332432 · fetched Nov 12, 2026
GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer PatientsPHASE1 · COMPLETED · started May 16, 2016ClinicalTrials.gov NCT02575404 · fetched Nov 12, 2026
Clinical Trial to Evaluate Efficacy of GR-MD-02 for Treatment of Liver Fibrosis in Patients With NASH With Advanced FibrosisPHASE2 · COMPLETED · started Sep 1, 2015ClinicalTrials.gov NCT02421094 · fetched Nov 12, 2026
An Open-Label, Phase 2a Study to Evaluate Safety and Efficacy of GR-MD-02 for Treatment of PsoriasisPHASE2 · COMPLETED · started Sep 1, 2015ClinicalTrials.gov NCT02407041 · fetched Nov 12, 2026
Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash CirrhosisPHASE2 · COMPLETED · started Jun 1, 2015ClinicalTrials.gov NCT02462967 · fetched Nov 12, 2026